Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Autolus Therapeutics (AUTL) over the last 6 years, with Dec 2024 value amounting to $52.3 million.

  • Autolus Therapeutics' Accumulated Expenses rose 10.06% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year increase of 10.06%. This contributed to the annual value of $52.3 million for FY2024, which is 32.07% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' Accumulated Expenses is $52.3 million, which was up 32.07% from $39.6 million recorded in FY2023.
  • Autolus Therapeutics' Accumulated Expenses' 5-year high stood at $52.3 million during FY2024, with a 5-year trough of $32,563 in FY2021.
  • Over the past 2 years, Autolus Therapeutics' median Accumulated Expenses value was $45.9 million (recorded in 2023), while the average stood at $45.9 million.
  • Per our database at Business Quant, Autolus Therapeutics' Accumulated Expenses plummeted by 99.88% in 2021 and then soared by 32.07% in 2024.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Accumulated Expenses stood at $27.8 million in 2020, then slumped by 99.88% to $32,563 in 2021, then reached $39.6 million in 2023, then soared by 32.07% to $52.3 million in 2024.